Study register · detail
Clear benefit
GRADE
High
60 citations
Samplek = 10 Studien
n = 7.390 Pat.
n = 7.390 Pat.
DurationStudy period
ControlNo or less frequent cannabis use
EndpointDevelopment of psychosis
Blindingunklar
DesignMeta-Analyse
Key finding
Meta-analysis shows significantly increased psychosis risk with weekly or more frequent cannabis use (RR=1,35-1,76), but no significant risk with less frequent use.
Summary
Systematic review + dose-response meta-analysis across k=10 studies (3 cohorts, 7 case-control, n=7.390, age 12–65 years); significant log-linear dose-response relationship between cannabis use frequency and psychosis risk. Restricted cubic splines model shows risk thresholds: RR=1,35 (95% CI 1,19–1,52) with weekly use, RR=1,76 (95% CI 1,47–2,12) with daily use; no significant risk with <weekly use (RR=1,01 yearly, RR=1,10 monthly).
P
PopulationPersons aged 12–65 years with varying cannabis use frequency, pooled n=7390
I
InterventionCannabis use (different frequencies: yearly, monthly, weekly, daily)
C
ControlNo or less frequent cannabis use
O
OutcomeLog-linear dose-response relationship: RR=1,01 (95%-CI 0,93–1,11) yearly; RR=1,10 (95%-CI 0,97–1,25) monthly; RR=1,35 (95%-CI 1,19–1,52) weekly; RR=1,76 (95%-CI 1,47–2,12) daily
Confidence in the evidence
High
The highest of four GRADE levels, the effect estimate is very reliable.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
Background: Epidemiological studies show a dose-response association between cannabis use and the risk of psychosis. This review aimed to determine whether there are identifiable risk-thresholds between the frequency of cannabis use and psychosis development.
Methods: Systematic search of Embase, MEDLINE, PsycINFO, CINAHL, and Web of Science for relevant studies (1 January 2010-26 April 2021). Case-control or cohort studies that investigated the relationship between cannabis use and the risk of psychosis development that reported effect estimates [odds ratios (OR), hazard ratios (HR), risk ratios (RR)] or the raw data to calculate them, with information on the frequency of cannabis consumption were included. Effect estimates were extracted from individual studies and converted to RR. Two-stage dose-response multivariable meta-analytic models were utilized and sensitivity analyses conducted. The Newcastle Ottawa Scale was used to assess the risk of bias of included studies.
Results: Ten original (three cohorts, seven case-control) studies were included, including 7390 participants with an age range of 12-65 years. Random-effect model meta-analyses showed a significant log-linear dose-response association between cannabis use frequency and psychosis development. A restricted cubic-splines model provided the best fit for the data, with the risk of psychosis significantly increasing for weekly or more frequent cannabis use [RR = 1.01, 95% confidence interval (CI) 0.93-1.11 yearly; RR = 1.10, 95% CI 0.97-1.25 monthly; RR = 1.35, 95% CI 1.19-1.52 weekly; RR = 1.76, 95% CI 1.47-2.12 daily].
Conclusion: Individuals using cannabis frequently are at increased risk of psychosis, with no significant risk associated with less frequent use. Public health prevention messages should convey these risk-thresholds, which should be refined through further work.
The impediment to action advances action.